You are here: Industry Insights > GlaxoSmithKline

News List

Cipla receives final approval for generic version of GlaxoSmithKline's IMITREX® (Sumatriptan Nasal Spray, 20 mg) prnasia
March 02, 2021
Cipla Limited today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the United States Food and Drug Administration (U.S. FDA).
AI to be most transformative technology for pharma, finds survey europeanpharmaceuticalreview
February 01, 2021
A new report suggests artificial intelligence (AI) will be the most disruptive technology in the pharmaceutical industry this year and beyond.
ViiV posts positive long-term data for two-drug HIV regimen Dovato pharmatimes
October 14, 2020
GlaxoSmithKline subsidiary ViiV Healthcare has reported new data for its two-drug HIV regimen Dovato, with hopes that the long-term data could encourage clinicians to switch from other triple regimen therapies.
GlaxoSmithKline signs manufacture deal with Samsung Biologics pharmaceutical-technology
May 26, 2020
GlaxoSmithKline has signed an agreement with South Korea-based Samsung Biologics for additional capacity to manufacture and supply its biopharmaceutical therapies.
European Medicines Agency accepts submission of GSK's Marketing Authorisation Application for Zejula (niraparib) in first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer prnasia
February 29, 2020
GlaxoSmithKline plc announced that the European Medicines Agency (EMA) has validated the company's Type II Variation (T2V) for Zejula (niraparib) as a maintenance treatment in the first-line setting for women with advanced ovarian cancer who responded to
U.S. FDA accepts GSK's sNDA application for Zejula (niraparib) for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer prnasia
February 25, 2020
GlaxoSmithKline plc today announced that the U.S. Food and Drug Administration (FDA) accepted the company's submission of a supplemental New Drug Application (sNDA) seeking approval of Zejula (niraparib) as a maintenance treatment in the first-line settin
Pfizer, GlaxoSmithKline Announce Joint Venture americanpharmaceuticalreview
August 02, 2019
Pfizer announced the closing of its joint venture with GlaxoSmithKline to combine the parties’ respective consumer healthcare businesses to create the world’s largest over-the-counter (OTC) business.
FDA OKs new administration options for GSK’s Nucala pharmatimes
June 11, 2019
GlaxoSmithKline’s Nucala (mepolizumab) has gained US Food and Drug Administration (FDA) approval for two new self-administration options, making the drug the first anti-IL5 biologic to give healthcare professionals the choice of how and where their patien
GlaxoSmithKline's booming Shingrix, after VIP invite, wins nod to tackle China fiercepharma
May 29, 2019
GlaxoSmithKline’s shingles vaccine Shingrix has continuously impressed industry watchers with its explosive growth. Now, the company has added another large market to its list: China.
Novartis brings in GlaxoSmithKline's Richard Saynor to lead turnaround of Sandoz unit firstwordpharma
April 25, 2019
Novartis announced Wednesday alongside its first-quarter financial results, that Richard Saynor, the current senior vice president of classic and established products, commercial and digital platforms at GlaxoSmithKline.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page